Education
About Us
Working with TipRanks
Follow Us
Novavax (NVAX)
NASDAQ:NVAX
NVAX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$5.01 - $15.22
Previous CloseN/A
Volume4.15M
Average Volume (3M)8.34M
Market Cap
$1.23B
Enterprise Value$721.89M
Total Cash (Recent Filing)$623.05M
Total Debt (Recent Filing)$228.49M
Price to Earnings (P/E)3.3
Beta1.58
Next Earnings
Nov 05, 2025EPS Estimate
-0.49Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.62
Shares Outstanding162,421,650
10 Day Avg. Volume8,590,948
30 Day Avg. Volume8,343,263
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.59
Enterprise Value/Revenue0.67
Enterprise Value/Gross Profit0.76
Enterprise Value/Ebitda1.46
Forecast
1Y Price Target
$10.00Price Target Upside26.58% Upside
Rating ConsensusHold
Number of Analyst Covering5
Bulls Say, Bears Say
Bulls Say
Cost ManagementNovavax has been successful in trimming operating expenses by about two-thirds from COVID highs and cleaning up its balance sheet.
Vaccine ApprovalThe approval of the 2025-2026 Nuvaxoid vaccine with a six-month refrigerated shelf-life makes the vaccine more attractive to distributors.
Vaccine PlatformAt the core of the positive view of Novavax is the company’s proprietary vaccine platform based on a recombinant protein nanoparticle and Matrix-M adjuvant.
Bears Say
Eligibility DecreaseThe number of U.S. adults eligible for COVID-19 boosters is projected to decrease by 49% due to new FDA guidelines and ACIP recommendations.
Market Share ReductionNovavax has reduced peak market share estimates for Nuvaxovid from 18% to 14% due to uncertainty in the COVID market.
Regulatory ChallengesThe higher burden of proof and cost for pivotal trials under the new FDA framework may raise the bar for signing new partnerships for Novavax's COVID-19/influenza combination (CIC) vaccine program.
Novavax News
NVAX FAQ
What was Novavax’s price range in the past 12 months?
Novavax lowest stock price was $5.01 and its highest was $15.22 in the past 12 months.
What is Novavax’s market cap?
Novavax’s market cap is $1.23B.
When is Novavax’s upcoming earnings report date?
Novavax’s upcoming earnings report date is Nov 05, 2025 which is in 60 days.
How were Novavax’s earnings last quarter?
Novavax released its earnings results on Aug 06, 2025. The company reported $0.62 earnings per share for the quarter, beating the consensus estimate of $0.008 by $0.612.
Is Novavax overvalued?
According to Wall Street analysts Novavax’s price is currently Undervalued.
Does Novavax pay dividends?
Novavax does not currently pay dividends.
What is Novavax’s EPS estimate?
Novavax’s EPS estimate is -0.49.
How many shares outstanding does Novavax have?
Novavax has 162,421,650 shares outstanding.
What happened to Novavax’s price movement after its last earnings report?
Novavax reported an EPS of $0.62 in its last earnings report, beating expectations of $0.008. Following the earnings report the stock price went up 12.63%.
Which hedge fund is a major shareholder of Novavax?
Currently, no hedge funds are holding shares in NVAX
Novavax Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$10.00 (26.58% Upside)
$10.00 (26.58% Upside)
Blogger Sentiment
Bullish
NVAX Sentiment 66%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 233.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.6%
Last 30 Days ▼ 1.2%
Last 30 Days ▼ 1.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-34.37%
12-Months-Change
Fundamentals
Return on Equity
30.06%
Trailing 12-Months
Asset Growth
-26.51%
Trailing 12-Months
Company Description
Novavax
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
NVAX Company Deck
NVAX Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted several positive achievements, including a significant milestone payment from the BLA approval in the U.S., successful cost reduction strategies, and promising data from the CIC and flu programs. However, these were somewhat offset by a notable decrease in total revenue compared to the previous year and the financial implications of a required post-marketing commitment study. Overall, the sentiment leans towards positive due to the outweighed highlights.View all NVAX earnings summariesNVAX Stock 12 Month Forecast
Average Price Target
$10.00
▲(26.58% Upside)
Technical Analysis
Anavex Life Sciences
―
CureVac
―
AbCellera Biologics
―
Pharvaris
―
Immunocore Holdings
―
Ownership Overview
0.39% Insiders
12.58% Mutual Funds
20.96% Other Institutional Investors
49.17% Public Companies and
Individual Investors